News | January 23, 2014

Embolizing Enlarged Prostates May Alleviate Symptoms

January 23, 2014 – Men with enlarged prostates can find relief with a non-surgical treatment that shrinks the gland, suggests research done on more than 100 patients and presented at the 26th annual International Symposium on Endovascular Therapy (ISET).
 
Prostate artery embolization (PAE) shrinks the prostate by temporarily blocking blood flow to the arteries that feed it. Benign prostate hyperplasia (BPH) affects most men as they age, including more than half by age 60 and 90 percent by age 85. BPH typically is treated with surgery or thermal ablation, which can cause side effects such as retrograde ejaculation or urinary incontinence.
 
University of Sao Paolo physicians have treated 120 patients, and 97 percent have reported improvement in symptoms and quality of life. Symptoms leading to re-embolization, surgery or medication therapy recurred in 14 percent of patients, who have been followed between three months and more than five years. 
 
Embolization is used to treat a variety of conditions, such as fibroid tumors and cancer. Physicians embolize by making a tiny incision in an artery in the groin, feeding a catheter to both prostate arteries and injecting fluid filled with microscopic beads, which block the blood vessels. It can be done using local anesthesia.
 
PAE is an experimental treatment in the United States. A study is underway to compare results of PAE to the standard surgical treatment, transurethral resection of the prostate (TURP), which requires general or spinal anesthesia.
 
For more information: www.iset.ge

Related Content

Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Virtual Phantoms Inc. Releases VirtualDose-IR
Technology | Radiation Dose Management | August 07, 2017
Virtual Phantoms Inc. announced the release of VirtualDoseIR, a tool for assessing organ dose from interventional...
Moffitt Cancer Center Enhances Patient Care with Toshiba Medical's Infinix-i 4-D
News | Interventional Radiology | August 03, 2017
Cancer patients at Moffitt Cancer Center in Tampa, Fla., now have access to advanced diagnostic imaging for fast and...
Synergy Radiology Associates Employs UroNav Fusion Biopsy System for Better Prostate Cancer Diagnosis
News | Biopsy Systems | July 17, 2017
Radiologists from Synergy Radiology Associates (SRA) in Houston are using the power of 3-D medical imaging and...
Siemens Healthineers Announces First U.S. Install of Artis Pheno Angiography System
News | Angiography | July 05, 2017
July 5, 2017 — Michigan Medicine recently became the first healthcare institution in the United States to install the
Augmenix Announces First New Zealand Prostate Cancer Patient Treated with SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | June 28, 2017
Augmenix Inc. announced that the first patient in New Zealand has been treated with SpaceOAR hydrogel at the Kathleen...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Royal College of Radiologists Publishes New Guidance on Interventional Oncology
News | Interventional Radiology | May 25, 2017
May 25, 2017 —The Royal College of Radiologists (RCR) has published a new edition of its guidance on the application
Overlay Init